For example, after receiving treatment with the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, over 80% of patients with chronic lymphocytic leukemia developed C481S mutations, leading to drug resistance. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.